Inga Odenholt, Elisabeth Löwdin, Otto Cars 

Slides:



Advertisements
Similar presentations
Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages
Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents
Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times  F.B. Spencker, L. Staber, T. Lietz,
Standardization and quality assurance for antimicrobial resistance surveillance of Streptococcus pneumoniae and Staphylococcus aureus within the European.
Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens.
In-vitro interaction of azithromycin and fluoroquinolones against gram-positive and gram-negative bacteria  Matthew W. Ruble, Deborah H. Gilbert, Stephen.
Grepafloxacin: microbiological properties
Approach to diagnosis of infective endocarditis
The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram- positive bacteria  M.J. Rybak  Clinical Microbiology and Infection 
Herpes zoster in non-hospitalized children
Antimicrobial Activity of SCH 27899, Oligosaccharide Member of the Everninomycin Class with a Wide Gram-Positive Spectrum  Ronald N. Jones, M.D., Mary.
In vitro activity of cefpirome and vancomycin in combination against gentamicin- susceptible and gentamicin-resistant Staphylococcus aureus  A. Carricajo,
Trends in quinolone susceptibility of Enterobacteriaceae among inpatients of a large university hospital: 1992–98  J. Robert, E. Cambau, K. Grenet, D.
Hydatid disease Clinical Microbiology and Infection
Link between intracellular pathogens and cardiovascular diseases
How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development  R. Bax  Clinical Microbiology.
Revision of linezolid disk diffusion quality control guidelines for testing Staphylococcus aureus ATCC 25923: an independent seven-laboratory trial  D.J.
How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach  D. Guillemot  Clinical Microbiology.
In vitro activity, postantibiotic effect and human monocyte activity of grepafloxacin against Legionella species  Jacques Dubois, Claude St-Pierre  Clinical.
Structure of grepafloxacin relative to activity and safety profile
Vector control: a cornerstone in the malaria elimination campaign
Pharmacodynamics of doxycycline
Evaluation of antibacterial activity of cefodizime, ceftriaxone and cefonicid in Klebsiella pneumoniae-infected guinea pigs  Lorenzo Drago, Barbara Mombelli,
Determination of in vitro postantibiotic effects in Staphylococcus aureus and Escherichia coli by [3H]thymidine incorporation  Magnús Gottfredsson, Helga.
Standardization and quality assurance for antimicrobial resistance surveillance of Streptococcus pneumoniae and Staphylococcus aureus within the European.
C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins
Multicenter study of the in vitro activity of cefepime in comparison with five other broad- spectrum antibiotics against clinical isolates of Gram-positive.
Training for the infectious diseases speciality in Norway
The antibacterial effects of ciprofloxacin and trovafloxacin against Streptococcus pneumoniae in an in vitro dynamic model  Matthew O'Brien, Thuy Quach,
Pharmacodynamic properties of HMR 3004, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time.
Cephalosporins: a pharmacological update
Epidemiology of opportunistic infections in AIDS patients
D. Esel, B. Sümerkan, S. Kocagöz  Clinical Microbiology and Infection 
Laboratory diagnosis and biosafety issues of biological warfare agents
Comparative in vitro pharmacodynamics of BO-2727, meropenem and imipenem against Gram-positive and Gram-negative bacteria  Inga Odenholt, Elisabeth Löwdin,
Sepsis and neutropenia induced by clozapine
Uncommon opportunistic fungi: new nosocomial threats
G. Kronvall  Clinical Microbiology and Infection 
André Bryskier  Clinical Microbiology and Infection 
In vitro selection of antibiotic resistance in Pseudomonas aeruginosa
Levofloxacin in the treatment of ventilator-associated pneumonia
The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae  J.M. Sierra,
Relapsing erythematous desquamating disorder in a child, with the same toxin- producing Staphylococcus aureus strain  Josette Raymond, Edouard Bingen,
Laboratory diagnosis of Clostridium difficile disease
T.M. File  Clinical Microbiology and Infection 
Epidemiology of penicillin resistance in Streptococcus pneumoniae isolates in eastern France  Daniel Talon, Blandine Mulin, Marie-Jeanne Dupont, Anne-Marie.
Single- and multistep selection study of the antipneumococcal activity of BMS compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin 
Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens.
Community-acquired pneumonia: epidemiologic and clinical consideration
Grepafloxacin: pharmacokinetics and tissue penetration
Pandemic lineages of extraintestinal pathogenic Escherichia coli
Lack of antimicrobial activity of sodium heparin for treating experimental catheter-related infection due to Staphylococcus aureus using the antibiotic-lock.
Andrew M. Middleton, Maureen V. Chadwick, Harold Gaya 
Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan  Y.-C. Hsieh, L.-Y. Chang, Y.-C. Huang, H.-C. Lin,
Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a working party  Dilip Nathwani, Christopher Conlon  Clinical.
Statin use and clinical outcomes among pneumonia patients
Clinical Microbiology and Infection
Clinical Microbiology and Infection
Overview of cefixime use in community-acquired infections
Granulocyte colony-stimulating factor (G-CSF) and interleukin (IL)-8 in sera from patients with Staphylococcus aureus septicemia  Bo Söderquist, Dan Danielsson,
The atypical pneumonias: clinical diagnosis and importance
Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe  Robert D. Fox  Clinical Microbiology.
Abstracts Clinical Microbiology and Infection
New oral cephalosporins in pediatric community-acquired infections
B.A. Cunha  Clinical Microbiology and Infection 
J.L. Balcázar  Clinical Microbiology and Infection 
G.C. Schito  Clinical Microbiology and Infection 
Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3- ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant.
Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a working party  Dilip Nathwani, Christopher Conlon  Clinical.
The future of diagnostic bacteriology
Presentation transcript:

Bactericidal effects of levofloxacin in comparison with those of ciprofloxacin and sparfloxacin  Inga Odenholt, Elisabeth Löwdin, Otto Cars  Clinical Microbiology and Infection  Volume 4, Issue 5, Pages 264-270 (May 1998) DOI: 10.1111/j.1469-0691.1998.tb00054.x Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 Time-killing curves of levofloxacin, ciprofloxacin and sparfloxacin against Streptococcus pneumoniae ATCC 6306 at a concentration reached in human serum 1 h after 500 mg IV (mean CFU/mL±SD). Limit of detection 10 CFU/mL. Clinical Microbiology and Infection 1998 4, 264-270DOI: (10.1111/j.1469-0691.1998.tb00054.x) Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 Time-killing curves of levofloxacin and ciprofloxacin against Staphylococcus aureus HBD 2 and 10 at a concentration reached in human serum 1 h after 500 mg IV (mean CFU/mL±SD). Limit of detection 10 CFU/mL. Clinical Microbiology and Infection 1998 4, 264-270DOI: (10.1111/j.1469-0691.1998.tb00054.x) Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 3 Time-killing curves of levofloxacin and ciprofloxacin against P. aeruginosa ATCC 27 853 and E. coli ATCC 25 922 at a concentration reached in human serum 1 h after 500 mg IV (mean CFU/mL±SD). Limit of detection 10 CFU/mL. Clinical Microbiology and Infection 1998 4, 264-270DOI: (10.1111/j.1469-0691.1998.tb00054.x) Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.